Moleculin Biotech, Inc.
MBRXDrugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
Liposomal Annamycin Injection in combination with Cytarabine Injection
Acute Myeloid Leukaemia (AML)
Cytarabine
Leukemia, Myeloid, Acute
Liposomal Annamycin (L-Annamycin)
Sarcoma,Soft Tissue
Liposomal Annamycin
Leukemia, Myeloid, Acute
MOL4239
Psoriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Liposomal Annamycin Injection in combination with Cytarabine Injection | Phase 3 | Acute Myeloid Leukaemia (AML) | - | - |
Cytarabine | Phase 2 | Leukemia, Myeloid, Acute | - | |
Liposomal Annamycin (L-Annamycin) | Phase 2 | Sarcoma,Soft Tissue | - | - |
Liposomal Annamycin | Phase 2 | Leukemia, Myeloid, Acute | - | - |
MOL4239 | Phase 2 | Psoriasis | - | - |
Leukemia, Myeloid, Acute
2 drugs in this indication
Acute Myeloid Leukaemia (AML)
1 drug in this indication
Sarcoma,Soft Tissue
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)